High-dose levofloxacin in community-acquired pneumonia: A randomized, open-label study

Clinical Drug Investigation

Volumn 32, Issue 9, 2012, Pages 569-576

  Lee, Jin Hwa ^a   Kim, Seo Woo ^a   Kim, Ji Hye ^a   Ryu, Yon Ju ^a   Chang, Jung Hyun ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

Azithromycin; Ceftriaxone; Community acquired pneumonia; Levofloxa cin

Indexed keywords

AZITHROMYCIN; CEFPODOXIME; CEFTRIAXONE; CORTICOSTEROID; LEVOFLOXACIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MALE; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THORAX RADIOGRAPHY; TREATMENT DURATION; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES;

EID: 84865108256     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11634640-000000000-00000     Document Type: Article

References (23)

1. Lim WS, Baudouin SV, George RC, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 Suppl. 3: iii1-55
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl. 2: 27-72
3. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-80 (Pubitemid 41829947)
4. Cilloniz C, Ewig S, Polverino E, et al. Microbial etiology of community acquired pneumonia and its relation to severity. Thorax 2011; 66: 340-6
5. FerrerM,Menendez R, Amaro R, et al. The impact of guidelines on the outcomes of community acquired and ventilator acquired pneumonia. Clin Chest Med 2011; 32: 491-505
6. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003; 63: 2769-802 (Pubitemid 38049994)
7. Grossman RF, Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med 2005; 118 Suppl. 7A: 29-38
8. Frank E, Liu J, Kinasewitz G, et al. A multicenter, openlabel, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community acquired pneumonia. Clin Ther 2002; 24: 1292-308 (Pubitemid 35026153)
9. Conte Jr JE, Golden JA, Mclver M, et al. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. Int J Antimicrob Agents 2006; 28: 114-21 (Pubitemid 44108608)
10. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37: 752-60 (Pubitemid 37153652)
11. Noreddin AM, Marras TK, Sanders K, et al. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500mg, 750mg and 1000mg once daily in plasma and epithelial lining fluid of hospitalized patients with community acquired pneumonia. Int J Antimicrob Agents 2004; 24: 479-84 (Pubitemid 39425161)
12. Dunbar LM, Khashab MM, Kahn JB, et al. Efficacy of 750 mg, 5 days levofloxacin in the treatment of community acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004; 20: 555-63 (Pubitemid 38525164)
13. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50 (Pubitemid 27044625)
14. Echols RM, Tillotson GS, Song JX, et al. Clinical trial design for mild to moderate community acquired pneumonia: an industry perspective. CID 2008; 47 Suppl. 3: 166-75
15. File TM, Garau J, Blasi F, et al. Guidelines for empiric antimicrobial prescribing in community acquired pneumonia. Chest 2004; 125: 1888-901 (Pubitemid 38648425)
16. Song JH, Jung KS, Kang MW, et al. Treatment guidelines for community acquired pneumonia in Korea: an evidence based approach to appropriate antimicrobial therapy. Tuberc Respir Dis 2009; 67: 281-302
17. File TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965-72 (Pubitemid 27383238)
18. File TM. Levofloxacin in the treatment of community acquired pneumonia. Can Respir J 1999; 6 Suppl. A: 35-9
19. Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998; 30: 397-404 (Pubitemid 28488229)
20. Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of community acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 2008; 179: 1269-77
21. Houck PM, MacLehose RF, Niederman MS, et al. Empiric antibiotic therapy and mortality among Medicare pneumonia in patients in 10 Western states: 1993, 1995, and 1997. Chest 2001; 119: 1420-6 (Pubitemid 32686024)
22. Ribelles JMQ, Tenias JM, Querol-Borras JMQ, et al. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization. Int J Antimicrob Agents 2005; 25: 75-83 (Pubitemid 40023350)
23. Kahn JB. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 2001; 47 Suppl. 3: 32-7 (Pubitemid 32823914)